Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – For hepatocellular carcinomas (HCC) larger than 2 cm, radiofrequency ablation (RFA) is the best ablative therapy, a meta-analysis shows – but for smaller…
NEW YORK (Reuters Health) – Adding trastuzumab (Herceptin) to standard chemotherapy can significantly improve event-free survival in women with HER2-positive locally advanced or inflammatory breast cancer, according to…
Miguel Materin, MD, Director of Ocular Oncology Section, Yale Eye Center, discusses uveal melanoma treatment which depends on saving the patient’s life before consideration of saving the eye…
NEW YORK (Reuters Health) – A substantial proportion of women with cervical cancer who receive curative-intent radiotherapy will soon develop pelvic fractures, clinicians from the University of Texas…
NEW YORK (Reuters Health) – Androgen suppression therapy – and its attendant side effects — may not be necessary for patients with intermediate-risk prostate cancer treated with combination…
NEW YORK (Reuters Health) – Endoscopic resection of large colonic polyps is a safe and cost-effective alternative to surgery, according to a paper in the December issue of…
NEW YORK (Reuters Health) – Nearly all patients have complications from chemoradiation for head and neck cancer, a study in the Archives of Otolaryngology: Head and Neck Surgery…
NEW YORK (Reuters Health) – Core needle biopsies seem almost as accurate as open biopsy in detecting breast cancer, and less prone to complications, a meta-analysis has found.…
NEW YORK (Reuters Health) – Breast cancer recurrence rates are lower with aromatase inhibitors than with tamoxifen, according to meta-analyses published online by the Journal of Clinical Oncology.…
NEW YORK (Reuters Health) – Children who are disease-free 5 years after a cancer diagnosis are still at risk for recurrence for another 20 years or more, new…
